



## Genenta to present **preliminary Phase I/II clinical data** on Temferon™ in glioblastoma multiforme at Chardan's 4<sup>th</sup> Annual Genetic Medicines Conference

September 30, 2020

MILAN (Italy) / NEW YORK (NY, USA) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that it will present new preliminary data from the Phase I/II TEM-GBM study of Temferon™ in patients affected with glioblastoma multiforme, at the 4<sup>th</sup> Virtual Annual Genetic Medicines Conference, hosted by Chardan on 5<sup>th</sup> and 6<sup>th</sup> of October 2020.

Pierluigi Paracchi, Chairman and Chief Executive Officer at Genenta Science and Dr. Carlo Russo, Chief Medical Officer and Head of Development, will present the data along with an overview of the company's pipeline and development of Temferon™ in two solid tumor indications.

### **Presentation Details:**

Date: Tuesday, October 6

Time (EDT): starting from 2:30pm

Registration at: [https://www.meetmax.com/sched/event\\_63347/conference\\_register.html](https://www.meetmax.com/sched/event_63347/conference_register.html)

### About Genenta Science

Genenta ([www.genenta.com](http://www.genenta.com)) has developed a strategy for ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to delivery immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Genenta's proprietary product is Temferon™.

The targeted expression of the immunomodulatory molecule in TEMs is achieved combining a transcriptional and post-transcriptional microRNA-mediated control. Thanks to these mechanisms, TEMs become capable of expressing the immunomodulatory molecule interferon-alpha (IFN-α) in the tumor microenvironment.

TEMs are endowed with a pro-angiogenic activity and are spontaneously and actively recruited by developing tumors to sustain their growth. Thanks to the immune-gene transfer, TEMs become the tool for the local delivery of the immunomodulatory molecule. In preclinical models, the local IFN-α release triggered both a direct (anti-angiogenic, pro-apoptotic) and an indirect anti-tumor effect (immune response).

In contrast to antigen-restricted Chimeric Antigen Receptor T cells (CAR-T), Temferon™ is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, which remains one of the main unresolved challenge in Immuno oncology. In addition, its immune-modulatory functions may trigger a long-lasting immune response towards multiple tumor antigens.

As a result, Temferon™ should be able to break the tumor-induced immune tolerance by reprogramming the tumor immune microenvironment.

Temferon is under investigation in a Phase I/II clinical trial in newly diagnosed Glioblastoma Multiforme patients.

Genenta's headquarter is in Milan (Italy) with an office in Alexandria Center's LaunchLabs, New York (NY, USA). The Company is part of Assobiotech, Italia StartUp, and ELITE (London Stock Exchange Group).

Co-founders: Pierluigi Paracchi, Ospedale San Raffaele (OSR), Prof. Luigi Naldini (Director SR-TIGET, San Raffaele Telethon Institute for Gene Therapy), and Dr. Bernhard Gentner (Hematologist and Physician-Scientist at OSR and SR-TIGET). Dr. Carlo Russo, MD serves as CMO & Head of Development. Genenta has raised €33,6M (\$39.2).

### Investor Relator - LifeSci Advisors:

Mary-Ann Chang, CFA

Managing Director

+44 7483 28.48.53

[mchang@lifesciadvisors.com](mailto:mchang@lifesciadvisors.com)

### Genenta Media/Investor Contact:

Valentina Brambilla, MSc

+39 388 789.15.41

[valentina.brambilla@genenta.com](mailto:valentina.brambilla@genenta.com)

### **GENENTA SCIENCE Srl**

OSR - DiBit 1 - Via Olgettina, 58 - 20132 Milan (Italy)

LaunchLabs - Alexandria Center, 14th Floor

430 East 29th Street - New York, NY 10016 (USA)